Amgen Builds Out Antibody Interests With $2.5bn Teneobio Buy
$900m Upfront
Executive Summary
Private California venture will bring additional expertise and novel platforms to acquisitive biotech giant as it looks to expand its interests in bispecific and multispecific antibody technologies.